Multiple myeloma (MM) is a hematologic malignancy defined by the clonal proliferation of
transformed plasma cells. Despite tremendous advances in the treatment paradigm of MM, a …

The emergence of various novel therapies over the last decade has changed the therapeutic
landscape for multiple myeloma. While the clinical outcomes have improved significantly …

Simple Summary Multiple myeloma (MM) is a frequent hematological malignancy
characterized by the uncontrolled growth of clonal plasma cells, primarily in the bone …

B-cell maturation antigen (BCMA)–specific chimeric antigen receptor (CAR) T cells have
substantial therapeutic potential in multiple myeloma (MM), but most patients eventually …

Immunotherapy has shown efficacy in relapsed multiple myeloma (MM). However, these
therapies may depend on a functional tumor immune microenvironment (iTME) for their …

The 15th edition of the Workshop on Recent Issues in Bioanalysis (15th WRIB) was held on
27 September to 1 October 2021. Even with a last-minute move from in-person to virtual, an …

Chimeric antigen receptor T‐cell (CAR‐T) therapy has become an important intervention in
the management of relapsed and relapsed/refractory multiple myeloma (MM). Currently, B …

Simple Summary Defining the specificity and biological sequalae induced by receptors
differentiated expressed in multiple myeloma cells are critical for the development of …

With recent advances in myeloma therapy, patients can achieve long-term remissions, but
eventually relapses will occur. Triple-class refractory myeloma (disease that is refractory to …

Collectively, hematological malignancies account for the fourth most common malignancy.
Myeloma and lymphoma are the most common types of hematological malignancies …